Serum Biomarker Tests Accurately Assess Stomach Mucosa Condition
|
By LabMedica International staff writers Posted on 10 Mar 2009 |
|
Serum biomarker tests were evaluated for their ability to differentiate between patients with healthy or diseased stomach mucosa: i.e., those with Helicobacter pylori gastritis or atrophic gastritis.
Risks for gastric cancer or peptic ulcer diseases are low in subjects with healthy stomach mucosa but are remarkably high in those with "diseased" stomach mucosa: i.e., in those with H. pylori gastritis or atrophic gastritis. Therefore, the differentiation between patients with healthy and diseased gastric mucosa is clinically important.
In a study performed by Dr. Iijima from the Division of Gastroenterology, Tohoku University Graduate School of Medicine (Sendai, Japan) and colleagues, the GastroPanel developed by Biohit Plc (Helsinki, Finland) was evaluated. In 162 outpatients the serum or plasma levels of gastrin-17 and H. pylori antibodies were measured from the same sample using an enzyme-linked immunosorbant assay (ELISA) technique. Pepsinogen I and pepsinogen II were also measured from the same sample using a conventional Japanese technique, and by the GastroPanel examination. Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H. pylori nonatrophic gastritis, or atrophic gastritis.
Pepsinogen I and pepsinogen II assays using the GastroPanel and the Japanese methods showed a highly significant correlation. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis, which was also verified by endoscopic biopsies. The GastroPanel examination revealed an additional 7 patients who had advanced atrophic gastritis limited to the antrum. When compared with the endoscopic biopsy findings, the GastroPanel examination classified patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity.
The study was published in the February 21, 2009 World Journal of Gastroenterology.
Related Links:
Tohoku University Graduate School of Medicine
Biohit Plc
 (3) (1).png)
Risks for gastric cancer or peptic ulcer diseases are low in subjects with healthy stomach mucosa but are remarkably high in those with "diseased" stomach mucosa: i.e., in those with H. pylori gastritis or atrophic gastritis. Therefore, the differentiation between patients with healthy and diseased gastric mucosa is clinically important.
In a study performed by Dr. Iijima from the Division of Gastroenterology, Tohoku University Graduate School of Medicine (Sendai, Japan) and colleagues, the GastroPanel developed by Biohit Plc (Helsinki, Finland) was evaluated. In 162 outpatients the serum or plasma levels of gastrin-17 and H. pylori antibodies were measured from the same sample using an enzyme-linked immunosorbant assay (ELISA) technique. Pepsinogen I and pepsinogen II were also measured from the same sample using a conventional Japanese technique, and by the GastroPanel examination. Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H. pylori nonatrophic gastritis, or atrophic gastritis.
Pepsinogen I and pepsinogen II assays using the GastroPanel and the Japanese methods showed a highly significant correlation. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis, which was also verified by endoscopic biopsies. The GastroPanel examination revealed an additional 7 patients who had advanced atrophic gastritis limited to the antrum. When compared with the endoscopic biopsy findings, the GastroPanel examination classified patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity.
The study was published in the February 21, 2009 World Journal of Gastroenterology.
Related Links:
Tohoku University Graduate School of Medicine
Biohit Plc
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Pipette
Accumax Smart Series
Rapid Molecular Testing Device
FlashDetect Flash10
Latest Immunology News
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read more
Molecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read more
Hematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Microbiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read more
Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Pathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read more
AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
Technology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
Industry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more
